C. Domènech

发表

The New Antitumor Drug ABTL0812 Inhibits the Akt/mTORC1 Axis by Upregulating Tribbles-3 Pseudokinase

P. Bragado, Jordi Espadaler Mazo, G. Velasco, 2015, Clinical Cancer Research.

The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells

J. Bosch-Barrera, G. Velasco, J. Lizcano, 2020, Autophagy.

ABTL0812 enhances antitumor effect of paclitaxel and reverts chemoresistance in triple‐negative breast cancer models

J. Lizcano, M. Yeste-Velasco, T. Puig, 2022, Cancer communications.

Anticancer effects of ABTL0812, a clinical stage drug inducer of autophagy-mediated cancer cell death, in glioblastoma models

M. Yeste-Velasco, G. Gravina, C. Festuccia, 2022, Frontiers in Oncology.

A first-in-human phase I/Ib dose-escalation clinical trial of the autophagy inducer ABTL0812 in patients with advanced solid tumours.

H. Colom, P. Gascón, J. Lizcano, 2021, European journal of cancer.

The antitumour drug ABTL0812 impairs neuroblastoma growth through endoplasmic reticulum stress-mediated autophagy and apoptosis

J. Lizcano, M. Segura, M. Yeste-Velasco, 2020, Cell Death & Disease.

Therapeutic potential of the new TRIB3-mediated cell autophagy anticancer drug ABTL0812 in endometrial cancer.

C. Moiola, N. Eritja, X. Matías-Guiu, 2019, Gynecologic oncology.

The novel proautophagy anticancer drug ABTL0812 potentiates chemotherapy in adenocarcinoma and squamous nonsmall cell lung cancer

P. Gascón, M. Mancino, P. Bragado, 2020, International journal of cancer.

The New Antitumor Drug ABTL0812 Inhibits the Akt/mTORC1 Axis by Upregulating Tribbles-3 Pseudokinase

P. Bragado, Jordi Espadaler Mazo, G. Velasco, 2015, Clinical Cancer Research.